BioPharma Dive February 14, 2024
The company and partner Biogen say that signs of demand from payers and prescribers suggest the launch of Zurzuvae is off to a good start.
Sage Therapeutics said its new medicine, the first oral treatment for postpartum depression, is off to an encouraging start, with signs of demand from prescribing doctors.
Sage and partner Biogen began selling the drug, Zurzuvae, in mid-December and on Wednesday Sage shared the first data from an estimated 10 days when doctors’ offices were open at the end of the month. During that time, physicians wrote about 120 prescriptions for the drug and 50 prescriptions were shipped and delivered to patients.
Net revenue from the drug during the short window in December totaled $1.6 million,...
Today's Sponsors
Today's Sponsor